AP NEWS

24 HOUR DEADLINE NOTICE: Kaskela Law LLC Announces Shareholder Class Action Lawsuit Against Esperion Therapeutics, Inc. and Encourages Investors with Losses in Excess of $250,000 to Immediately Contact the Firm

July 5, 2018

RADNOR, Pa.--(BUSINESS WIRE)--Jul 5, 2018--A shareholder class action lawsuit has been filed against Esperion Therapeutics, Inc. (NASDAQ: ESPR) (“Esperion” or the “Company”) on behalf of investors who purchased the Company’s common stock between February 22, 2017 and May 1, 2018, inclusive (the “Class Period”).

FINAL DEADLINE NOTICE: Investors who purchased Esperion’s common stock during the Class Period may, no later than July 6, 2018, seek to be appointed as a lead plaintiff of the investor class.

Esperion investors are encouraged to contact Kaskela Law LLC (David Seamus Kaskela, Esq.) at (484) 258 – 1585 or (888) 715 – 1740 to discuss their important legal rights and options with respect to this action prior to July 6, 2018. Investors may also visit to submit their information to the firm online.

On May 2, 2018, Esperion announced results from its second pivotal Phase 3 study for its cholesterol-lowering medication. Esperion also disclosed that, although the trial met certain primary endpoints, there were 13 deaths in the treatment group as compared to only two in the control group. Following this news, shares of the Company’s stock declined $24.75 per share, or over 35%, to close on May 2, 2018 at $45.75.

The shareholder class action lawsuit alleges, among other things, that Esperion and certain of its senior executive officers made false and misleading statements and/or failed to disclose to investors that the Company’s cholesterol-lowering medication entailed serious undisclosed safety risks, including death. The complaint further alleges that, as a result of the foregoing, investors purchased Esperion’s stock at artificially inflated prices during the Class Period and suffered significant investment losses following the Company’s May 2, 2018 disclosure.

Esperion investors are encouraged to contact Kaskela Law LLC at (484) 258 – 1585 or (888) 715 – 1740, or via , to discuss their legal rights and options prior to July 6, 2018. Kaskela Law LLC exclusively prosecutes shareholder actions in state and federal courts throughout the country on behalf of investors. For additional information about Kaskela Law LLC please visit www.kaskelalaw.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180705005015/en/

CONTACT: KASKELA LAW LLC

David Seamus Kaskela, Esq.

201 King of Prussia Road

Suite 650

Radnor, PA 19087

484-258-1585

888-715-1740

skaskela@kaskelalaw.com

www.kaskelalaw.com

KEYWORD: UNITED STATES NORTH AMERICA PENNSYLVANIA

INDUSTRY KEYWORD: PROFESSIONAL SERVICES LEGAL

SOURCE: Kaskela Law LLC

Copyright Business Wire 2018.

PUB: 07/05/2018 08:00 AM/DISC: 07/05/2018 08:01 AM

http://www.businesswire.com/news/home/20180705005015/en

AP RADIO
Update hourly